Trial · NCT05913427
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluation of the activity of the combination regimen (EDP-M plus progesterone (EDP-MP) versus EDP-M plus placebo) in advanced/ metastatic patients with ACC. | 18 months | Comparison of proportion of patients attaining an Objective Response (Objective Response Rate, ORR), evaluated by RECIST criteria between the 2 treatment arms. |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in serum cortisol from baseline in the two treatment arms; |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in serum UFC from baseline in the two treatment arms; |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in serum salivary cortisol from baseline in the two treatment arms; |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in ACTH from baseline in the two treatment arms; |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in serum 11-deoxycortisol from baseline in the two treatment arms; |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in serum aldosterone from baseline in the two treatment arms; |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in serum PRA from baseline in the two treatment arms; |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in serum androstenedione from baseline in the two treatment arms; |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in serum DHEA-S from baseline in the two treatment arms; |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in serum progesterone from baseline in the two treatment arms; |
| Secondary | Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; | 18 months | Changes in serum total testosterone from baseline in the two treatment arms; |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05913427/registered